Carl Dieffenbach Ph.D
Director, DAIDS, NIAID
National Institute of Health, Bethesda, MD
Title:Drug Development for HIV: We have come so far, and we are not yet done
Carl W. Dieffenbach, Ph.D., serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than $1 billion and a staff of more than 150 federal employees. He played a key role in restructuring the DAIDS-supported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, foundations, and industry. In 1992, he joined DAIDS as the chief of the preclinical therapeutics group. Upon his appointment, Dr. Dieffenbach spearheaded important research initiatives that accelerated the progress of basic research on HIV pathogenesis and directly resulted in new clinical studies of novel AIDS therapies. In 1996, he was promoted to Director of the DAIDS Basic Sciences Program, where he remained until being selected as the division director in 2008. In 2011, Dr. Dieffenbach received the Distinguished Alumnus Award of the Department of Chemistry and Biochemistry, University of Maryland.
Lawrence Vernetti, Ph.D.
Director of Early Drug Safety, University of Pittsburgh Drug Discovery Institute Pittsburgh, PA
Ethan Russo, M.D.
Director of Research and Development International Cannabis and Cannabinoids Institute, Czech Republic, EU
Paul Dunman, Ph.D.
Principal Investigator, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY
Bo Rode Hansen, MBA, PhD
President and Chief Executive Officer Genevant Sciences Boston, MA
Drug Discovery-2019 Speakers
Shuji Ogino, MD, Ph.D.
Chief, Dept. of Pathology BWH, Harvard Medical School Boston, MA, USA
Elmar Nurmemmedov, Ph.D., MBA
Director of Drug Discovery, Principal Investigator of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, CA
Maurizio Pellecchia, Ph.D.
Professor of Biomedical Sciences UCR School of Medicine CA, USA
Stephanie C. Oestreich, MPA
EVP, Head BRIDGEs Partnerships North America Evotec (US) Inc., USA
Thomas Webster, Ph.D.
Department Chair, Chemical Engineering Northeastern University MA, USA
Paul C. Trippier, Ph.D.
Department of Pharmaceutical Sciences Texas Tech University Health Sciences Center, Amarillo, TX
Ravindra Peravali, Ph.D.
Head, Screening Center, Institute of Toxicology and Genetics (ITG), Karlsruhe Institute of Technology, Germany
Dana M. Lambert, B.Sc.(Pharm), R.Ph., Ph.D.
Founder, Principal Pharmaceutical Inventor and CEO, Andira Pharmaceuticals,
Alexander McCampbell, Ph.D.
Senior Director Principal Neurology Scientist Biogen, Boston, MA
Anna Jacobs, Ph.D.
Scientist Walter Reed Army Institute of Research Silver Spring, MD
USG-United Scientific Group A non-profit OrganizationPlano, TX 75024, USA